Company: GEHC
Filing Date: 2025-04-30
Form Type: 10-Q
Source: 0001932393-25-000014
Chunk: 74

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-04-30
Form: 10-Q
Item: Item 1
Chunk 74
---
 Cross-currency swaps— — — 8 — Foreign currency forward and option contracts— — — 2 — Effects of net investment hedges(1)— — — 10 — Interest rate swaps(2)— — — (45)— Debt basis adjustment on Long-term borrowings— — — 38 — Effects of fair value hedges— — — (6)— Foreign currency forward contracts(12)(3)— — — Other derivatives(3)— — 5 — 20 Effects of derivatives not designated as hedging instruments(12)(3)5 — 20 (1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the three months ended March 31, 2025 and 2024.(2) Amount includes $(4) million and $(6) million of interest expense on interest rate derivatives for the three months ended March 31, 2025 and 2024, respectively.(3) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.(4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income.FAIR VALUE MEASUREMENTS.The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.

20

Table of Contents                 

Fair Value of Assets and Liabilities Measured on a Recurring BasisAs of March 31, 2025As of December 31, 2024Level 1Level 2Level 3TotalLevel 1Level 2Level 3TotalAssets:Money market funds$— $230 $— $230 $— $312 $— $312 Investment securities27 — — 27 32 — — 32 Derivatives— 136 — 136 — 145 — 145 Liabilities:Derivatives— 160 — 160 — 155 — 155 Contingent consideration— — 40 40 — — 34 34 Cash equivalentsAs of March 31, 2025 and December 31, 2024, Cash, cash equivalents, and restricted cash of $2,473 million and $2,889 million, respectively